

Corvus Pharmaceuticals, Inc.
Form DEFA14A
April 24, 2019
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

Filed by the Registrant
Filed by a Party other than the Registrant
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under §240.14a-12

Corvus Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Edgar Filing: Corvus Pharmaceuticals, Inc. - Form DEFA14A

Check box if any part of the fee is offset as provided by Exchange Act Rule 0 11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

000004 ENDORSEMENT_LINE _____ SACKPACK MR A SAMPLE DESIGNATION (IF ANY) ADD
1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 C 1234567890 Online Go to www.envisionreports.com/crvs or scan the QR
code — login details are located in the shaded bar below. Votes submitted electronically must be received by 11:59
p.m., Eastern Time, on June 19, 2019 Stockholders Meeting Notice 1234 5678 9012 345 Important Notice Regarding
the Availability of Proxy Materials for the Corvus Pharmaceuticals, Inc. Stockholder Meeting to be Held on June 20,
2019. Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the
2019 Annual Meeting of Stockholders of Corvus Pharmaceuticals, Inc. (the “Annual Meeting”) are available on the
Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted
on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents
only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to
access and review all of the important information contained in the proxy materials before voting. The proxy
statement and annual report to stockholders are available at: www.envisionreports.com/crvs Easy Online Access —
View your proxy materials and vote. Step 1: Go to www.envisionreports.com/crvs. Step 2: Click on Cast Your Vote
or Request Materials. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selections as
instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also
help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy
Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for
requesting a copy. Please make your request as instructed on the reverse side on or before June 10, 2019 to facilitate
timely delivery. 2 N O T C O Y 0320XB

Stockholders Meeting Notice The 2019 Annual Meeting of Stockholders of Corvus Pharmaceuticals, Inc. will be held on June 20, 2019 at 1:00 p.m., Pacific Time, at 863 Mitten Road, Suite 102, Burlingame, CA 94010. Proposals to be voted on at the Annual Meeting are listed below along with the Board of Directors' recommendations. The Board of Directors recommends a vote FOR the election of the director nominees named in Proposal 1 and FOR Proposal 2. 1. To elect three Class III Directors with terms to expire at the 2022 annual meeting of stockholders; and 2. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Here's how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/crvs. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with "Proxy Materials Corvus Pharmaceuticals, Inc." in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 10, 2019.
